Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 8/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | SGK1 | O00141 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91006 | 0.87 | MKNK1 (0.40) | MKNK1MKNK2DRD4USP30JAK2 | |
| SCHEMBL91000 | 0.86 | GRIA2 (0.44) | MKNK1MKNK2DRD4USP30JAK2 | |
| SCHEMBL90939 | 0.85 | USP30 (0.52) | MKNK1MKNK2DRD4USP30MEN1 | |
| SCHEMBL91023 | 0.84 | MKNK1 (0.57) | MKNK1MKNK2DRD4MEN1KMT2A | |
| SCHEMBL91001 | 0.82 | USP30 (0.54) | USP30MEN1KMT2APOLB | |
| SCHEMBL8594304 | 0.82 | MKNK1 (0.40) | MKNK1MKNK2USP30MEN1KMT2A | |
| SCHEMBL91004 | 0.81 | DRD4 (0.57) | MKNK1MKNK2DRD4MEN1KMT2A | |
| SCHEMBL8576803 | 0.81 | SCN9A (0.38) | USP30MEN1KMT2APGRHTT | |
| SCHEMBL90995 | 0.81 | MEN1 (0.46) | MKNK1MKNK2DRD4USP30MEN1 | |
| SCHEMBL90870 | 0.79 | DRD4 (0.48) | MKNK1MKNK2DRD4USP30MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299066-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-8129372-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | MKNK1 3443/4885MKNK2 2861/4885DRD4 577/4885 |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | MKNK1 3443/4885MKNK2 2861/4885DRD4 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.